MYO

Insider Trading Activity: Thomas F Kirk, a director at $MYO, purchased 7,400 shares for approximately $37,000, increasing his holdings by about 3.0%, bringing his total to 255,933 shares. In the past six months, there have been three insider trades involving $MYO stock, with one purchase and two sales.

Institutional Investor Movements: In the latest quarter, 44 institutional investors increased their positions in $MYO stock while 18 reduced theirs, indicating mixed sentiment among institutional stakeholders regarding the company's stock.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Financial Performance: Myomo, Inc. reported a record revenue of $12.1 million for Q4 2024, marking a 154% increase from the previous year, with significant growth in unit sales and positive cash flow from operations for the first time in its history.

Operational Growth: The company added a record 657 new candidates to its patient pipeline in Q4 2024, resulting in a total of 1,389 candidates, while also achieving a gross margin of 71.4%, up from 65.3% in the same quarter last year.

Financial Performance: Myomo, Inc. reported a record revenue of $12.1 million for Q4 2024, a 154% increase from the previous year, and achieved its first-ever positive cash flow from operations of $3.4 million. The company anticipates 2025 revenues between $50 million to $53 million.

Operational Growth: The company received a record 233 MyoPro authorizations and orders in Q4 2024, with a total patient pipeline of 1,389 candidates, reflecting a 33% increase year-over-year. Myomo aims to continue this growth trajectory into 2025.

Major Earnings Announcements: Key companies reporting earnings after the market close on Monday include Oracle Corporation, Asana, Limbach Holdings, Vail Resorts, and Lineage Cell Therapeutics.

Additional Earnings Releases: Other companies set to release their earnings include CHRS, FTK, GECC, LFMD, MC, MYO, RDW, and YALA.

Financial Reporting Announcement: Myomo, Inc. will report its financial results for the fourth quarter and year ending December 31, 2024, on March 10, 2025, followed by a conference call at 4:30 p.m. ET.

Company Overview: Myomo specializes in wearable medical robotics, particularly the MyoPro product line, which aids individuals with neurological disorders and upper-limb paralysis by restoring arm and hand function through non-invasive technology.

Public Offering Announcement: Myomo, Inc. has announced a public offering of 3,000,000 shares of common stock at $5.00 per share, expecting to raise approximately $15 million before expenses, with plans to close the offering around December 6, 2024.

Use of Proceeds: The funds will be used to enhance revenue growth through increased advertising and headcount, support product development for the MyoPro line, and cover general corporate expenses.

Myomo's Public Offering: Myomo (MYO) has filed a preliminary prospectus supplement for a planned public offering.

Portfolio Access: Users need to sign in to access their portfolio related to this offering.

Myomo's Public Offering Announcement: Myomo, Inc. plans to conduct an underwritten public offering of its common stock and may grant the underwriter a 30-day option for additional shares, with proceeds aimed at accelerating revenue growth and funding product development.

About Myomo's Technology: Myomo specializes in wearable medical robotics, particularly the MyoPro device, which helps restore arm function in patients with neurological disorders, enabling them to perform daily activities independently.

Analyst Upgrades and Downgrades: Several Wall Street analysts have adjusted their price targets and ratings for various companies, with notable upgrades for monday.com, Myomo, iHeartMedia, SentinelOne, and NVIDIA, while Phunware received a downgrade.

Price Target Changes: Analysts from firms like Needham, Ascendiant Capital, and Deutsche Bank have increased price targets for multiple stocks, while Morgan Stanley slightly reduced the target for International Flavors & Fragrances, reflecting mixed sentiments in the market.

Real-time Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them make informed decisions daily.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and alerts generated by Benzinga reporters.

Myomo's New Contracts: Myomo, Inc. has secured its first in-network contracts with Blue Cross Blue Shield of Massachusetts and Paradigm, allowing its MyoPro device to be covered by private insurance for patients with neurological disorders and upper-limb paralysis.

Impact on Patient Care: These contracts mark a significant milestone for Myomo, as they aim to make the MyoPro a standard care option, enhancing the ability of patients to perform daily activities and potentially improving their quality of life.

Financial Results Announcement: Myomo, Inc. will report its third-quarter financial results on November 6, 2024, and host a conference call at 4:30 p.m. ET with CEO Paul R. Gudonis and CFO David Henry.

Company Overview: Myomo specializes in wearable medical robotics, specifically the MyoPro product line, which aids individuals with upper-limb paralysis by restoring arm and hand function through non-invasive EMG signal sensing.

Myomo's Participation in Virtual Summit: Myomo, Inc. will have its CEO Paul Gudonis and CFO David Henry participate in a "Fireside Chat" at the 2024 Maxim Healthcare Virtual Summit from October 15-17, where they will discuss the company's advancements in wearable medical robotics for patients with upper-limb paralysis.

About Myomo's Technology: Myomo specializes in developing the MyoPro product line, a powered orthosis that helps restore arm function for individuals with neurological disorders, enabling them to perform daily activities independently and potentially return to work.

Myomo Academy Launch: Myomo, Inc. has launched the Myomo Academy, a learning management system aimed at professionals in Orthotics & Prosthetics and Rehabilitation, during the 2024 AOPA National Assembly in Charlotte, NC.

Educational Focus: The academy offers a structured curriculum with courses ranging from introductory to advanced levels, designed to enhance clinician knowledge on myoelectric orthosis technology and improve patient care outcomes.

Investor Conferences Participation: Myomo, Inc. will participate in two investor conferences in September 2024, including the HC Wainwright Annual Global Investment Conference and the Lake Street Best Ideas Growth Conference, where management will present and hold one-on-one meetings with investors.

Company Overview: Myomo is a wearable medical robotics company that develops the MyoPro product line, designed to restore arm and hand function for individuals suffering from neurological disorders and upper-limb paralysis, enabling them to perform daily activities and live independently.

Financial Performance: Myomo reported a 77% increase in product revenue for Q2 2024, driven by the inclusion of Medicare Part B patients and an increase in average selling price to approximately $47,500. The company achieved record patient pipeline additions and authorizations during this quarter.

Growth Strategy: Myomo is expanding its operational capacity and workforce to meet growing demand, including plans to move to a larger production facility. The company aims to enhance its marketing efforts and build relationships with orthotics and prosthetics clinics to further drive growth in 2025.

Financial Results Announcement: Myomo, Inc. will report its financial results for the second quarter of 2024 on August 6, 2024, and will host a conference call at 4:30 p.m. ET the same day.

About Myomo: Myomo is a company that develops wearable medical robotics to assist individuals with upper-limb paralysis, offering products like MyoPro to help restore functionality and improve daily living activities.

Helen of Troy Limited Earnings Report:

• Helen of Troy Limited (HELE) experienced a sharp decline in shares after reporting lower-than-expected first-quarter earnings and revising its FY25 guidance.
• Quarterly earnings were reported at 99 cents per share, missing the analyst consensus estimate of $1.59.
• Quarterly sales stood at $416.85 million, falling short of the analyst consensus estimate of $446.22 million.
• The stock price of Helen of Troy dropped by 30.3% to $62.06 following the news.

Stock Movements:

• Soligenix, Inc. (SNGX) saw a 195% increase in shares after announcing positive interim results for extended HyBryte treatment.
• uniQure N.V. (QURE) observed a 55.4% rise in shares due to updated interim data on AMT-130 for Huntington’s disease treatment.
• Various other companies like Pineapple Energy Inc., Anew Medical, Inc., Expensify, Inc., and more experienced significant stock movements, both positive and negative.